RxDoctor Payments DataLook up a doctor →

Robin Anderson, NP

Family · Portage, INNPI 1780012245

Payments from drug & device makers

$332,611in general payments, 2019–2025

Across 1,274 payments — averaging $261.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$319K
  • AbbVie$3K
  • Novo Nordisk$1K
  • Nestle Healthcare Nutrition Inc.$1K
  • Recordati_rare_diseases_inc.$1K
  • Amgen$988
  • plus $6K from 45 others

What the payments were for

  • Consulting fees$5,5002%
  • Speaking & faculty fees$241,33073%
  • Travel & lodging$62,41219%
  • Food & beverage$23,2047%
  • Education$1640%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$332,611 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.

See all family providers in Indiana

Medicare billing

Part B allowed, 2024
$55,909
Medicare patients
91
Services billed
2,163

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KorlymMifepristone24$903,672
IsturisaOsilodrostat Phosphate12$298,795
OzempicSemaglutide50$106,816
MounjaroTirzepatide60$94,163
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/734$59,291
Repatha SureclickEvolocumab46$47,523
LinzessLinaclotide23$27,783
FarxigaDapagliflozin Propanediol16$23,479
Humulin R U-500Insulin Regular, Human14$21,702
Nurtec OdtRimegepant Sulfate11$17,606
TirosintLevothyroxine Sodium41$12,018
SynthroidLevothyroxine Sodium39$5,592
VyvanseLisdexamfetamine Dimesylate14$5,445
NovologInsulin Aspart25$3,836
Dexlansoprazole DrDexlansoprazole11$3,620

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Corcept TherapeuticsKorlym$319,145$903,67224 claims
Recordati_rare_diseases_inc.Isturisa$1,101$298,79512 claims
Novo NordiskOzempic, Novolog$1,166$110,65175 claims
Lilly USA, LLCMounjaro$297$94,16360 claims
AbbVieLinzess, Synthroid, Armour Thyroid$2,777$34,95575 claims
AstraZenecaFarxiga$241$23,47916 claims
PfizerNurtec Odt$416$17,60611 claims
IBSA Pharma Inc.Tirosint$303$12,01841 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$236$5,44514 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$22$40019 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.

Other family in Portage

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →